Cargando…
CCN5/WISP2 and metabolic diseases
Obesity and type 2 diabetes increase worldwide at an epidemic rate. It is expected that by the year 2030 around 500 million people will have diabetes; predominantly type 2 diabetes. The CCN family of proteins has become of interest in both metabolic and other common human diseases because of their e...
Autores principales: | Grünberg, John R, Elvin, Johannes, Paul, Alexandra, Hedjazifar, Shahram, Hammarstedt, Ann, Smith, Ulf |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Netherlands
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5842198/ https://www.ncbi.nlm.nih.gov/pubmed/29247377 http://dx.doi.org/10.1007/s12079-017-0437-z |
Ejemplares similares
-
Restricted Adipogenesis in Hypertrophic Obesity: The Role of WISP2, WNT, and BMP4
por: Gustafson, Birgit, et al.
Publicado: (2013) -
Overexpressing the novel autocrine/endocrine adipokine WISP2 induces hyperplasia of the heart, white and brown adipose tissues and prevents insulin resistance
por: Grünberg, John R., et al.
Publicado: (2017) -
Metabolic Effects of CCN5/WISP2 Gene Deficiency and Transgenic Overexpression in Mice
por: Alami, Tara, et al.
Publicado: (2021) -
The role of CCN4/WISP-1 in the cancerous phenotype
por: Nivison, Mary P, et al.
Publicado: (2018) -
Prospects and Perspectives for WISP1 (CCN4) in Diabetes Mellitus
por: Maiese, Kenneth
Publicado: (2020)